

AMENDMENTS TO THE SPECIFICATION

Please insert the following paragraph on page 1 of the specification, after the title of the invention.

This application is a U.S. national phase application under 35 U.S.C. § 371 of international application PCT/CA00/00515, filed May 4, 2000, which claims benefit of the filing date of U.S. provisional patent application no. 60/132,592, filed May 5, 1999 (now abandoned).

Please replace the paragraph on page 3, lines 15-21, with the following new paragraph.

In another type of amyloidosis seen in patients with Type II diabetes, the islet amyloidogenic protein, IAPP, has been shown to induce β -islet cell toxicity *in vitro*. Hence, appearance of IAPP fibrils in the pancreas of Type II diabetic patients could contribute to the loss of the β islet cells (Langerhans) and organ dysfunction.